Please assess the completion status of the following clinical trial:

Trial Title: Nasal High Flow Therapy for the Treatment of Respiratory Insufficiencies During Sleep

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and Women aged ≥ 18 years~* Heart Failure from ischemic or non-ischemic dilated cardiomyopathy for ≥ 6 months~* Left ventricular systolic dysfunction (LVEF ≤45% by echocardiography performed within 3 months of the screening visit, or if not within 3 months, a justification provided by the cardiologist for why a repeat echocardiography is not required, for example, because the subject's condition has remained stable since their echocardiography). All echocardiography must be within a maximum of 1 year of the screening visit.~* New York Heart Association Class II or III after optimization of medical therapy~* Stable Clinical Status on stable optimal medical therapy for ≥ 1 month before entry~Exclusion Criteria:~* Unstable angina~* Myocardial infarction within the last 12 months~* Cardiac surgery within the previous 6 months~* Pregnancy~* Unwilling or unable to provide informed consent~* Uncontrolled arrhythmias~* Severe valvular heart disease~* Current/prior use of mechanical ventilation (including CPAP). At the investigator's discretion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic PSG/PG, PSG w. nasal high flow therapy (Type: EXPERIMENTAL): All patients recruited will undergo a diagnostic sleep study, either a full in laboratory attended polysomnography (PSG), or an in-home polygraphy (PG). If respiratory insufficiencies with Cheyne-Stokes respiration (CSR) are detected, these patients will undergo an overnight in laboratory attended PSG on a nasal high flow therapy device to test the primary endpoint of this study. Patients without respiratory insufficiencies after the first PSG/PG will take no further part in the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).